ClinicalTrials.gg
TerminatedNCT03468543Updated Jun 5, 2019Results posted

Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects

An Early Phase 1 interventional study of Memantine Hydrochloride MR Prototype Capsule Formulation A and Memantine Hydrochloride MR Prototype Capsule Formulation B in Gastric Retention and Healthy, sponsored by Lyndra Inc.. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-05.

Sponsored by Lyndra Inc. · Early Phase 1, Interventional, and Basic science

Why this study was terminated
Per protocol stopping rules

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jul 2017, registered Mar 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

To assess how long modified release (MR) memantine hydrochloride prototype capsule formulations stay in the stomach as determined by magnetic resonance imaging (MRI).

Read the detailed description

This is a single center, open-label, single dose, 5-period study in 24 healthy male and female subjects, with an optional Period 6, if required. It is expected the study will be executed in 3 cohorts of 8 subjects, with each cohort participating in up to 2 study periods (total of up to 6 study periods). Cohort 3 may be conducted in parallel with Cohort 2.

Subjects will be dosed in a sequential manner, as appropriate. Each subject will be administered up to 2 regimens (2 different prototype capsule formulations) across 2 study periods. There will be a minimum 35-day interval between each dose administration.

Subjects will have an MRI scan performed on Days 2, 4, 7, 10 and 14 of each period to assess the gastric retentive properties of the formulation.

02

Conditions studied

  • Gastric Retention
  • Healthy
03

In context

Lead sponsor

Lyndra Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects.
  2. of 18.0 to 32.0 kg/m2.
  3. Subjects must demonstrate their ability to swallow a test capsule at screening.
  4. Must provide written .

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have received any medicinal product in a clinical research study within the previous 3 months.
  2. Subjects who have previously been enrolled in this study.
  3. History of any drug or alcohol abuse in the past 2 years.
  4. Current smokers and those who have smoked within the last 12 months.
  5. Individuals with medical history relating to the gastrointestinal tract and potential for complications, thereof
  6. Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) results.
  7. Serious adverse reaction or serious to any drug or the formulation .
  8. Individuals with to MRI imaging.

Other protocol defined criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation A; then formulation B; following each administration MRI will be performed for up to 14 days

    Drug: Memantine Hydrochloride MR Prototype Capsule Formulation A · Drug: Memantine Hydrochloride MR Prototype Capsule Formulation B · Procedure: Magnetic Resonance Imaging

  • Experimental
    Cohort 2

    Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation C; then formulation D; following each administration MRI will be performed for up to 14 days

    Drug: Memantine Hydrochloride MR Prototype Capsule Formulation C · Drug: Memantine Hydrochloride MR Prototype Capsule Formulation D · Procedure: Magnetic Resonance Imaging

  • Experimental
    Cohort 3

    Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation E; followed by MRI for up to 14 days

    Drug: Memantine Hydrochloride MR Prototype Capsule Formulation E · Procedure: Magnetic Resonance Imaging

Interventions

  • DrugMemantine Hydrochloride MR Prototype Capsule Formulation A

    Memantine HCl MR capsule formulation will be administered orally in a single dose

    Also known as: Memantine HCl Capsule Formulation A (50 mg)

  • DrugMemantine Hydrochloride MR Prototype Capsule Formulation B

    Memantine HCl MR capsule formulation will be administered orally in a single dose

    Also known as: Memantine HCl Capsule Formulation B (50 mg)

  • DrugMemantine Hydrochloride MR Prototype Capsule Formulation C

    Memantine HCl MR capsule formulation will be administered orally in a single dose

    Also known as: Memantine HCl Capsule Formulation C (50 mg)

  • DrugMemantine Hydrochloride MR Prototype Capsule Formulation D

    Memantine HCl MR capsule formulation will be administered orally in a single dose

    Also known as: Memantine HCl Capsule Formulation D (50 mg)

  • DrugMemantine Hydrochloride MR Prototype Capsule Formulation E

    Memantine HCl MR capsule formulation will be administered orally in a single dose

    Also known as: Memantine HCl Capsule Formulation E (50 mg)

  • ProcedureMagnetic Resonance Imaging

    MRI will be performed on specified days according to protocol

    Also known as: MRI

06

What researchers measure

Primary outcomes

  1. Gastric Retention by Magnetic Resonance Imaging (MRI)

    Number of Participants with Gastric Retention by Magnetic Resonance Imaging (MRI), as measured after dosing

    Time frame: 7 Days

07

Results

Posted Jun 5, 2019
Limitations and caveats
The trial was prematurely ended after the dosing of three subjects.

Participant flow

Participant flow — Overall Study
MilestoneCohort 1
Started3
Completed0
Not completed3
Withdrew: Protocol stopping rules met3

Outcome measures

PrimaryGastric Retention by Magnetic Resonance Imaging (MRI)

Number of Participants with Gastric Retention by Magnetic Resonance Imaging (MRI), as measured after dosing

Time frame:
7 Days
Reported as:
Count of participants · Participants
Gastric Retention by Magnetic Resonance Imaging (MRI)
ParticipantsCohort 1
Gastric Retention by Magnetic Resonance Imaging (MRI)2

Adverse events

Collected over Adverse events were collected for five weeks after each dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/3 (0%)1/3 (33.3%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventCohort 1
foreign bodyInjury, poisoning and procedural complications1/3
Most frequent other events
Most frequent other events
EventCohort 1
presyncopeNervous system disorders1/3
cryingGeneral disorders1/3
non-cardiac chest painGeneral disorders1/3
anxietyPsychiatric disorders1/3
abdominal discomfortGastrointestinal disorders1/3
abdominal painGastrointestinal disorders1/3
dysphagiaGastrointestinal disorders1/3
nauseaGastrointestinal disorders1/3
vomitingGastrointestinal disorders1/3

Baseline characteristics

Cohorts 2 and 3 were not executed, as the study was stopped during Cohort 1

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Total
Mean33.7 ± 12.3——33.7 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Total
Female0——0
Male3——3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Total
American Indian or Alaska Native0——0
Asian0——0
Native Hawaiian or Other Pacific Islander0——0
Black or African American1——1
White2——2
More than one race0——0
Unknown or Not Reported0——0
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Cohort 3Total
United Kingdom3——3
08

Study locations

1 site
  • Quotient Sciences (formerly Quotient Clinical)
    Ruddington, Nottingham NG11 6JS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Sep 2017, 1 month.

Results were first posted in Jun 2019, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2018
First posted
Mar 16, 2018
StartActual
Jul 26, 2017
Primary completionActual
Sep 18, 2017
CompletionActual
Sep 18, 2017
Results first posted
Jun 5, 2019
Last update
Jun 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03468543
Lead sponsor
Lyndra Inc.
Responsible party
Sponsor
First posted
Mar 16, 2018
Start date
Jul 26, 2017
Primary completion
Sep 18, 2017
Completion
Sep 18, 2017
Results posted
Jun 5, 2019
Last update
Jun 5, 2019

Study contacts

Stuart Mair, MBChB, DRCOG
study director · Quotient Clinical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion